At MarketClub, our mission is to help you become a better trader. Our passion is creating superior trading tools to help you achieve your goals—no matter which way the markets move—we promise objective and unbiased recommendations not available from brokers.

Here’s great news from a member…

“First, let me say how great your staff is. Very cordial, informative and friendly for sure.

Direct to trading: Years ago I made a bundle in the tech boom, yet, gave it back to the market simply by not selling. Since that time I’ve studied, gone to many seminars, opened real and demo accounts, purchased IBD, Vector Vest, Optionetics, Investools and numerous others programs. They’re all good in their own right.

However, one program stands out, i.e., INO’s MarketClub. Its the first program I open to review a stock or fx pair and the last one I close. I have

Following through on yesterday’s gains stocks took the lead and moved higher as volume tracked higher. A very bullish sign to see stocks moving higher with higher volume especially right after a day where prices advanced on lower trade. All was well and good with stocks until the final hour of trading where we began to see selling pressure. The selling pressure was enough to send the S&P 500 and Dow Jones Industrial Average into negative territory but the NASDAQ was able to slip in a small gain. Preliminary volume indicates NASDAQ saw higher trade while the NYSE declined avoiding a distribution day. A positive sign is we saw IBD indexes lead the market and we’ll await to see if volume on the IBD indexes came in higher. In summary, not a terrible day following yesterday’s move, but signs of …

top longs/(shorts) w/ TOTAL returns since 1st purchase making me money TODAY: ASCA 48% SOLR 40% INOD 40% KONG 28% ARST 25% (MOS 46% CHTT 15%)

Today was owned by the banking sector as the “Bank Stress Tests” were released today. By in large this stress was viewed vastly different from all sides of the aisle. Regardless of anyone’s opinion, the market’s opinion was positive as banks roared higher pushing the NYSE composite Index and S&P500 higher. Lagging behind was the NASDAQ composite index and the IBD indexes. It shouldn’t be a major surprise seeing the banks leading for one day as the stress tests showed most banks can withstand further downside, but we’ll need to see leadership from the IBD indexes. Once again, we did see major support for the NASDAQ and other indexes showing there is a bullish tint …

Vistaprint Limited is a Bermuda company that provides online customized marketing products and services to small businesses and consumers in over 120 countries. Right now, business is very good and if estimates are any indication the good times are still rolling now and will be in the future also.

VPRT has some amazing growth the past eight quarters in EPS and sales. EPS has grown 25%, 38%, 45%, 60%, 60%, 36%, 66%, and 38% the past eight quarters. Sales has grown, during that time, 60%, 59%, 64%, 53%, 52%, 44%, 32%, and 31%. This kind of growth, during a recession, is nothing short of something spectacular. What is even more promising is that 2009 and 2010 YOY EPS estimates are for 38% and 18% increases. This current growth, along with future expectations, makes this one of the strongest stocks out there.

Not only …

Stocks were hit hard from the onset, even leaders found themselves being sold. Ben Bernanke was testifying on the hill while traders were dumping stocks. Selling accelerated as the day wore on but were able to find footing prior to lunch time. Stocks then were hit hard after 2pm hitting new lows but support was able to come in. Stocks once again were able to avoid a nasty distribution day if the NASDAQ had gone out on its lows. This market is once again proving there is an underlying bid to the market.

Two key levels were held today and an important moving average. The NASDAQ was able to hold 1750 which happens to be its 200 day moving average while the S&P500 was able to hold a psychological level of 900. Holding the 200dma is very important level for the …

Since Donald Coxe’s departure from BMO towards the end of last year, I have been inundated with enquiries about whether his much-revered “Basic Points” research reports would still be published. The good news is that Donald is planning on resuming these reports, and a new issue may very well appear later this month.

In the meantime, Donald has also resumed his weekly audio commentaries, which can be accessed by clicking here or on his image in the right-hand sidebar of this site.

The latest recording was made on February 6 (althought the webcast site incorrectly mentions January 30). A full transcript of this recording was produced and is shared with you in the paragraphs below (courtesy of Green

Today can be called nothing other than nasty as most of the indexes made round trips back to either six-year or eleven-year lows, following a nasty selloff that came on very heavy volume. Volume picked up on every exchange as finally some signs of panic selling hit the market.

This selling took the markets off around 5% to 6% and a lot of stocks were just walloped. Now while I have continued to talk about the nasty downtrend this market is in and how well my shorts have been doing: top short holdings and total returns: IPHS 44% POT 65% GGB 72% SBAC 66% CYT 69% MOS 74% CETV 89% CPRT 28% AZO 24% RDK 17% AMX 49% PLCE 38% CAJ 34% SPG 52% CEO 51% AAPL 50% ENB 24% K 18% ARB 67% AMSG 20% SPW 77% RIMM 58% LLL 37% CEDC 65% APD 55% OKE 46% SDA 80% TITN

If today proves that headlines don’t mean anything in the short or long-term of the market. I don’t know what would make you believe that news stories are just ways for journalist to describe what is happening. After waking up and going over the news stories of the morning I expected the market to be up big or down big as a lot of action was going on out there.

Of course, when I go to take a look at the US Bourses it became clear that the headlines did little to drive the market anywhere. That should help people realize that it is not the news that drives the market but the market of buyers and sellers that drive the market.

One of the for surest things I thought I would see today with all the active headlines was at least heavy volume. Proving that supply and demand and what

A stock that I have stumbled on recently in one of my price and volume scans has me quite excited that I have found a young gem that could turn into a monster stock.

This stock is Aecom Technology Corporation (ACM) and is a provider of construction management and planning services to the transportation, facilities, and environmental markets. And these are the perfect markets to be in according to the growth in this outstanding company.

Earnings have been stellar, with EPS growth the past six quarters of 100%, 83%, 93%, 81%, 12%, and 59%. Sales, the past eight quarters, have been just as impressive with growth of 46%, 37%, 26%, 26%, 21%, 23%, 15%, and 7%.
Despite the growth in sales slowing a bit, the overall trend is extremely healthy.

This includes the 2008 and 2009 estimates which are expected to show EPS rising 29% and 19% those two years respectively. This current growth …

Pluristem Therapeutics works to commercialize cellular bio-therapies for the treatment of several degenerative, ischemic and autoimmune conditions. In a release that was largely overlooked last week, Pluristem conveyed the success of recent clinical trials, showing the pronounced effectiveness of its PLacental eXpanded (PLX) cells in treating Inflammatory Bowel Disease (IBD).

Pluristem defines its PLX product as mesenchymal stromal cells (MSCs) that have been expanded using the company’s proprietary PluriX™ 3-D bioreactor. Basically, MSCs are undifferentiated, protoplasmic placental cells.

In the study conducted, mice which were afflicted with IBD were administered PLX cells intrarectally, while a control group was treated with a saline solution. Pluristem’s treatment was shown to greatly reduce colon lesions associated with IBD in both macroscopic and microscopic evaluations, as compared to the control subjects.

Pluristem President and CEO, Zami Aberman stated: “This trial’s favorable results, which demonstrate our PLX cells’ ability to treat Inflammatory Bowel Disease, as